Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash

On November 14, MPM BioImpact reported in a U.S. Securities and Exchange Commission filing that it sold out its MoonLake Immunotherapeutics position, reducing exposure by $14.8 million in the third quarter.According to a U.S. Securities and Exchange Commission filing dated November 14, MPM BioImpact fully sold its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) during the third quarter. The fund disposed of 313,571 shares, eliminating a position that previously made up 2.6% of its assets under management. The move represented an estimated $14.8 million reduction based on quarterly average prices.Top holdings after the filing:  Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool